-
1.发明授权公开(公告)号：US11944612B2
公开(公告)日：2024-04-02
申请号：US17881874
申请日：2022-08-05
IPC分类号： A61K31/4439 , A61K9/16 , A61K9/48
CPC分类号： A61K31/4439 , A61K9/1605 , A61K9/4858 , A61K9/4866
摘要： Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens.
-
公开(公告)号：US11746100B2
公开(公告)日：2023-09-05
申请号：US17242731
申请日：2021-04-28
发明人： Qing Xu , Carsten Alt , Zhe Li , Shahul Nilar , Peter Michael Rademacher , Calvin Wesley Yee
IPC分类号： C07D401/14 , C07D401/04 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D471/08 , C07D491/056 , C07D498/08
CPC分类号： C07D401/14 , C07D401/04 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D471/08 , C07D491/056 , C07D498/08
摘要： The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I′ and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
-
3.发明公开公开(公告)号：US20230174504A1
公开(公告)日：2023-06-08
申请号：US18102440
申请日：2023-01-27
发明人： Fang Wang , Youqian Deng , Morin Mae Frick , Xiang Wang
IPC分类号： C07D401/04
CPC分类号： C07D401/04 , C07B2200/13
摘要： The present disclosure relates to processes for preparing a compound of Formula (I)
-
公开(公告)号：US20230159553A1
公开(公告)日：2023-05-25
申请号：US17921905
申请日：2021-04-28
发明人： Qing Xu , Zhe Li , Shahul Nilar
IPC分类号： C07D495/04 , C07D519/00
CPC分类号： C07D495/04 , C07D519/00
摘要： The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
-
公开(公告)号：US20230015823A1
公开(公告)日：2023-01-19
申请号：US17777909
申请日：2020-11-17
发明人： Carla B. Washington
IPC分类号： A61K31/4439 , A61K9/20 , A61P7/00 , A61K45/06 , A61K31/4196
摘要： Provided herein are methods of using voxelotor for the treatment of sickle cell disease in patients also having severe hepatic impairment. Also provided herein are methods for administering voxelotor and avoiding or lessening adverse drug interactions with a CYP3A4 inducer or inhibitor. Also provided herein are methods for avoiding interactions with voxelotor, a moderate CYP3A4 inhibitor.
-
公开(公告)号：US11548880B2
公开(公告)日：2023-01-10
申请号：US16865625
申请日：2020-05-04
发明人： Zhe Li
IPC分类号： C07D413/06 , A61K31/5377 , A61K31/541 , C07D417/06 , C07D401/06 , C07D211/22 , C07D403/06 , C07D265/30 , A61P7/06
摘要： The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.
-
公开(公告)号：US11530191B2
公开(公告)日：2022-12-20
申请号：US17026690
申请日：2020-09-21
发明人： Brian W. Metcalf , Zhe Li , Qing Xu , Stephen L. Gwaltney, II , Jason R. Harris , Calvin W. Yee
IPC分类号： C07D401/04 , C07D213/30 , A61K31/445 , A61K31/5375 , C07D401/14 , C07D405/14 , C07D401/12 , C07D471/04 , C07D257/04 , C07D487/04 , C07D231/56 , C07D211/62 , C07D213/64 , C07C65/30 , C07F7/08 , A61K8/49 , C07D211/70 , C07D213/69 , C07D227/08 , C07D405/04
摘要： Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
-
公开(公告)号：US20220395492A1
公开(公告)日：2022-12-15
申请号：US17885238
申请日：2022-08-10
发明人： Zhe Li , Stephan D. Parent , Travis Houston
IPC分类号： A61K31/4439 , C07D401/04 , A61P11/00 , A61P25/28 , A61P35/00 , A61P1/04
摘要： Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).
-
公开(公告)号：US11452720B2
公开(公告)日：2022-09-27
申请号：US16923498
申请日：2020-07-08
发明人： Zhe Li , Stephan D. Parent , Travis Houston
IPC分类号： A61K31/4439 , C07D401/04 , A61P11/00 , A61P25/28 , A61P35/00 , A61P1/04
摘要： Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).
-
公开(公告)号：US20220267337A1
公开(公告)日：2022-08-25
申请号：US17665942
申请日：2022-02-07
发明人： Lina Q. Setti , Shahul Nilar , Zhe Li , Ming Yu , Manuel Zancanella
IPC分类号： C07D487/04
摘要： The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.
-
-
-
-
-
-
-
-
-
搜索结果
109 条记录 (耗时 0.032 秒)
